Insilico Medicine and China Medical System Expand AI Collaboration in CNS Drug Discovery

July 13, 2026
Insilico Medicine and China Medical System Holdings have announced an expanded partnership to co-develop AI-powered treatments for central nervous system diseases, with potential milestone payments of up to 1.2 billion RMB.

Insilico Medicine and China Medical System Holdings announced an additional collaboration in drug discovery for central nervous system diseases in a press release. The partnership builds on an earlier agreement signed earlier this year and focuses on developing a therapy that targets a new mechanism of action identified by Insilico’s PandaOmics platform.

Under the agreement, the two companies will jointly advance research and development by combining Insilico’s generative AI platform with CMS’s clinical and commercialization capabilities. Insilico will be eligible for milestone payments of up to about 1.2 billion RMB, along with royalties on future sales.

The partnership will integrate Insilico’s AI-enabled drug discovery and development expertise with CMS’s experience in clinical research, regulatory processes, and market access. The collaboration aims to accelerate the transition of promising compounds from early discovery to clinical application.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

07/13
AT&T and Ericsson Demonstrate 5G-Based Drone Detection at Texas Stadium
07/10
Matillion Releases Maia Foundation for Google BigQuery
07/10
Supermicro Launches Kubernetes Edge AI Appliances with Red Hat and Everpure
07/10
Leidos and Rune Partner on AI Logistics for Indo-Pacific Military Operations
07/10
Dun & Bradstreet Debuts Risk Analytics Plugin for Cursor AI Platform

More from: Life Sciences

07/10
RyboDyn Awarded $1.3 Million Grant from U.S. Department of War for Lung Cancer Therapies
07/10
Sanyou Biopharmaceuticals Introduces GEOTA Platform for Drug Research
07/10
Lucile Packard Children's Hospital Deploys R-Zero Physical AI for Energy Optimization
07/10
Children’s Hospital of Philadelphia Receives $38.9 Million ARPA-H Award for Personalized Gene Editing Research
07/10
Collectly Launches AI Billing Integration on Epic Connection Hub

Subscribe to Enterprise AI Brief

Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like